Pain Communication Toolkit for Caregivers of Alzheimer's Patients
(PICT Trial)
Trial Summary
The trial information does not specify whether participants need to stop taking their current medications.
The Pain Identification and Communication Toolkit (PICT) has shown promise in a pilot trial by training caregivers to better recognize and communicate about pain in dementia patients, which is often underdetected and undermanaged. This suggests that PICT could help improve pain management by empowering caregivers with the skills needed to identify and report pain effectively.
12345The Pain Identification and Communication Toolkit (PICT) has been evaluated in a pilot trial for caregivers of people with dementia, focusing on training for pain assessment and communication. The study did not report any safety concerns, suggesting it is generally safe for use in humans.
12467The Pain Communication Toolkit is unique because it focuses on training caregivers to better observe and communicate about pain in Alzheimer's patients, rather than directly treating the pain itself. This approach empowers caregivers to play a crucial role in pain management by improving their ability to recognize and report pain symptoms, which is often challenging in patients who cannot communicate effectively.
148910Eligibility Criteria
This trial is for caregivers over 21 years old who speak English, are cognitively intact, and provide weekly care to someone with dementia or cognitive impairment and chronic pain enrolled in a PACE program. The person with dementia must not be in hospice or have a terminal illness with less than 6 months life expectancy.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Pain Identification and Communication Toolkit (PICT) intervention, consisting of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist.
Follow-up
Participants are monitored for changes in pain management and caregiver self-efficacy at 1, 3, and 6 months post-treatment.